Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Sells $10,950.84 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Earl Martin Douglas sold 6,404 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $10,950.84. Following the transaction, the senior vice president now directly owns 587,848 shares of the company's stock, valued at approximately $1,005,220.08. This represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Allogene Therapeutics Stock Up 1.2 %

Allogene Therapeutics stock traded up $0.02 during trading hours on Wednesday, reaching $1.64. 2,197,203 shares of the company's stock were exchanged, compared to its average volume of 2,824,648. The firm's 50 day simple moving average is $2.06 and its 200 day simple moving average is $2.45. Allogene Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $5.78. The firm has a market capitalization of $343.86 million, a PE ratio of -1.05 and a beta of 0.83.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ALLO shares. William Blair reaffirmed an "outperform" rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Allogene Therapeutics in a research report on Friday, November 8th. Finally, Piper Sandler lowered their target price on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating for the company in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.73.

Institutional Trading of Allogene Therapeutics

Several large investors have recently made changes to their positions in ALLO. Private Advisor Group LLC acquired a new stake in shares of Allogene Therapeutics in the 3rd quarter valued at about $34,000. Algert Global LLC acquired a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at about $35,000. MML Investors Services LLC acquired a new stake in shares of Allogene Therapeutics in the 3rd quarter valued at about $56,000. AQR Capital Management LLC acquired a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at about $64,000. Finally, EP Wealth Advisors LLC grew its stake in shares of Allogene Therapeutics by 125.6% in the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company's stock valued at $69,000 after buying an additional 13,625 shares during the period. 83.63% of the stock is currently owned by institutional investors and hedge funds.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.